Download PDF
Semin Thromb Hemost 2020; 46(02): 176-182
DOI: 10.1055/s-0040-1702170
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Fibrinolysis and the Immune Response in Trauma

Robert L. Medcalf
1   Molecular Neurotrauma and Haemostasis Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Victoria, Australia
,
Charithani B. Keragala
1   Molecular Neurotrauma and Haemostasis Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Victoria, Australia
,
Dominik F. Draxler
1   Molecular Neurotrauma and Haemostasis Laboratory, Australian Centre for Blood Diseases, Central Clinical School, Monash University, Victoria, Australia
2   Department of Cardiology, University Hospital of Bern, Bern, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
18 February 2020 (online)

    Permissions and Reprints

Abstract

It has long been known that the fibrinolytic system becomes activated following trauma. At first glance, this is not at all surprising and would appear to be in response to coagulation and the apparent need to remove blood clots and restore blood flow. However, in a bleeding patient, the opposite is what is actually needed. Therefore, one may ask why the fibrinolytic system gets activated in the first place or is there another purpose? Or is it that the waxing and waning of hemostasis in such severely injured patients creates a “moving target” such that the fibrinolytic system itself is constantly responding to changing circumstances? Depending on the injury modalities and the time point post injury, the fibrinolytic system could be either turned on or off. Various theories now abound that offer new insights into the turmoil and paradoxes associated with the fibrinolytic system in this unique setting and the use of antifibrinolytic agents. While this presents one conundrum, there is also another dimension to add to this discussion that has nothing to do with hemostasis per se but rather with the modulation of other critical processes that are also essential for optimal recovery following severe injury. Indeed, overwhelming data are now supporting an important role of the fibrinolytic system in the removal of necrotic tissue (mortolysis) and as a modulator of the innate immune response. Therefore, what is really going on when the fibrinolytic system decides to go into overdrive and generate plasmin, albeit even briefly after a traumatic event? Moreover, what other consequence may occur when antifibrinolytic agents are administered? This review will address this developing story and will outline a hypothesis that places the fibrinolytic system as a gateway to a myriad of processes that are not only linked to fibrin removal but are also broader players in the modulation of innate immunity.

Keywords

fibrinolysis - immune response - trauma - inflammation - antifibrinolytic agents
 

  • References

  • 1 Dastre A. Fibrinolyse dans le sang. Arch Physiol 1893; 5: 661
    PubMedGoogle Scholar
  • 2 Bier OE. Action anticoagulante et fibrinolytique de l'extract des glands salivaires d'une chauve-souris hematophage (desmodus rufus). C R Soc Biol (Paris) 1932; 110: 129-131
    PubMedGoogle Scholar
  • 3 Hawkey C. Plasminogen activator in saliva of the vampire bat Desmodus rotundus. Nature 1966; 211 (5047): 434-435
    PubMedGoogle Scholar
  • 4 Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58 (04) 485-502
    CrossrefPubMedGoogle Scholar
  • 5 Astrup T, Permin PM. Fibrinolysis in the animal organism. Nature 1947; 159 (4046): 681
    PubMedGoogle Scholar
  • 6 Sobel GW, Mohler SR, Jones NW, Dowdy ABC, Guest MM. Urokinase: an activator of plasma profibrinolysin extracted from urine. Am J Physiol 1952; 171: 768-769
    PubMedGoogle Scholar
  • 7 MacFarlane RG, Pilling J. Observations on fibrinolysis; plasminogen, plasmin, and antiplasmin content of human blood. Lancet 1946; 2 (6425): 562-565
    PubMedGoogle Scholar
  • 8 Gaffney PJ, Edgell TA, Whitton CM. The haemostatic balance -- Astrup revisited. Haemostasis 1999; 29 (01) 58-71
    PubMedGoogle Scholar
  • 9 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270 (24) 14477-14484
    CrossrefPubMedGoogle Scholar
  • 10 Hendriks D, Wang W, Scharpé S, Lommaert MP, van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034 (01) 86-92
    CrossrefPubMedGoogle Scholar
  • 11 Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100 (01) 86-92
    CrossrefPubMedGoogle Scholar
  • 12 Miles LA, Parmer RJ. Plasminogen receptors: the first quarter century. Semin Thromb Hemost 2013; 39 (04) 329-337
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Pennica D, Holmes WE, Kohr WJ. , et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli . Nature 1983; 301 (5897): 214-221
    CrossrefPubMedGoogle Scholar
  • 14 Okamoto S, Nakajima T, Okamoto U. , et al. A suppressing effect of ε-amino-N-caproic acid on the bleeding of dogs, produced with the activation of plasmin in the circulatory blood. Keio J Med 1956; 8 (04) 247-256
    PubMedGoogle Scholar
  • 15 McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012; 72 (05) 585-617
    CrossrefPubMedGoogle Scholar
  • 16 Shakur H, Roberts I, Bautista R. , et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376 (9734): 23-32
    CrossrefPubMedGoogle Scholar
  • 17 Roberts I, Shakur H, Afolabi A. , et al; CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377 (9771): 1096-1101 , 1101.e1–1101.e2
    CrossrefPubMedGoogle Scholar
  • 18 Medcalf RL. The traumatic side of fibrinolysis. Blood 2015; 125 (16) 2457-2458
    CrossrefPubMedGoogle Scholar
  • 19 Dobson GP, Doma K, Letson HL. Clinical relevance of a p value: does tranexamic acid save lives after trauma or postpartum hemorrhage?. J Trauma Acute Care Surg 2018; 84 (03) 532-536
    CrossrefPubMedGoogle Scholar
  • 20 Binz S, McCollester J, Thomas S. , et al. CRASH-2 study of tranexamic acid to treat bleeding in trauma patients: a controversy fueled by science and social media. J Blood Transfus 2015; 2015: 874920
    CrossrefPubMedGoogle Scholar
  • 21 Walsh M, Shreve J, Thomas S. , et al. Fibrinolysis in trauma: “myth,” “reality,” or “something in between”. Semin Thromb Hemost 2017; 43 (02) 200-212
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Schöchl H, Maegele M, Solomon C, Görlinger K, Voelckel W. Early and individualized goal-directed therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med 2012; 20: 15
    CrossrefPubMedGoogle Scholar
  • 23 Moore HB, Moore EE, Gonzalez E. , et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg 2014; 77 (06) 811-817 , discussion 817
    CrossrefPubMedGoogle Scholar
  • 24 Moore EE, Moore HB, Gonzalez E. , et al. Postinjury fibrinolysis shutdownr Rationale for selective tranexamic acid. J Trauma Acute Care Surg 2015; 78 (06) (Suppl. 01) S65-S69
    CrossrefPubMedGoogle Scholar
  • 25 Moore HB, Moore EE, Neal MD. , et al. Fibrinolysis shutdown in trauma: historical review and clinical implications. Anesth Analg 2019; 129 (03) 762-773
    CrossrefPubMedGoogle Scholar
  • 26 Cardenas JC, Wade CE, Cotton BA. , et al; PROPPR Study Group. TEG lysis shutdown represents coagulopathy in bleeding trauma patients: analysis of the PROPPR cohort. Shock 2019; 51 (03) 273-283
    CrossrefPubMedGoogle Scholar
  • 27 Cardenas JC, Wade CE, White NJ. A Reply to “Carriage Before the Horse”, a Letter to the Editor in Reference to “TEG Lysis Shutdown Represents Coagulopathy In Bleeding Trauma Patients: Analysis of the PROPPR Cohort” (2019; 51 (3): 273: 283). Shock 2019; 52 (06) 640-641
    CrossrefPubMedGoogle Scholar
  • 28 Curry NS, Davenport R, Pavord S. , et al. The use of viscoelastic haemostatic assays in the management of major bleeding: a British Society for Haematology Guideline. Br J Haematol 2018; 182 (06) 789-806
    CrossrefPubMedGoogle Scholar
  • 29 Roberts I. Fibrinolytic shutdown: fascinating theory but randomized controlled trial data are needed. Transfusion 2016; 56 (Suppl. 02) S115-S118
    CrossrefPubMedGoogle Scholar
  • 30 Mitra B, Mazur S, Cameron PA. , et al; PATCH-Trauma Study Investigators. Tranexamic acid for trauma: filling the ‘GAP’ in evidence. Emerg Med Australas 2014; 26 (02) 194-197
    CrossrefPubMedGoogle Scholar
  • 31 WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389 (10084): 2105-2116
    CrossrefPubMedGoogle Scholar
  • 32 Johnston LR, Rodriguez CJ, Elster EA, Bradley MJ. Evaluation of military use of tranexamic acid and associated thromboembolic events. JAMA Surg 2018; 153 (02) 169-175
    CrossrefPubMedGoogle Scholar
  • 33 Moore HB, Moore EE, Huebner BR. , et al. Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis. J Surg Res 2017; 220: 438-443
    CrossrefPubMedGoogle Scholar
  • 34 Myles PS, Smith JA, Forbes A. , et al; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017; 376 (02) 136-148
    CrossrefPubMedGoogle Scholar
  • 35 CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019; 394 (10210): 1713-1723
    CrossrefPubMedGoogle Scholar
  • 36 Raza I, Davenport R, Rourke C. , et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 2013; 11 (02) 307-314
    CrossrefPubMedGoogle Scholar
  • 37 Hayakawa M, Maekawa K, Kushimoto S. , et al. Hyperfibrinolysis in severe isolated traumatic brain injury may occur without tissue hypoperfusion: a retrospective observational multicentre study. Crit Care 2017; 21 (01) 222
    CrossrefPubMedGoogle Scholar
  • 38 Stettler GR, Moore EE, Moore HB. , et al. Redefining postinjury fibrinolysis phenotypes using two viscoelastic assays. J Trauma Acute Care Surg 2019; 86 (04) 679-685
    CrossrefPubMedGoogle Scholar
  • 39 Cotton BA, Harvin JA, Kostousouv V. , et al. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg 2012; 73 (02) 365-370 , discussion 370
    CrossrefPubMedGoogle Scholar
  • 40 MacFarlane RG, Biggs R. Fibrinolysis; its mechanism and significance. Blood 1948; 3 (10) 1167-1187
    CrossrefPubMedGoogle Scholar
  • 41 O'Mullane MJ, Baker MS. Loss of cell viability dramatically elevates cell surface plasminogen binding and activation. Exp Cell Res 1998; 242 (01) 153-164
    CrossrefPubMedGoogle Scholar
  • 42 Samson AL, Borg RJ, Niego B. , et al. A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury. Blood 2009; 114 (09) 1937-1946
    PubMedGoogle Scholar
  • 43 Samson AL, Knaupp AS, Sashindranath M. , et al. Nucleocytoplasmic coagulation: an injury-induced aggregation event that disulfide crosslinks proteins and facilitates their removal by plasmin. Cell Rep 2012; 2 (04) 889-901
    CrossrefPubMedGoogle Scholar
  • 44 Draxler DF, Daglas M, Fernando A. , et al. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis. J Thromb Haemost 2019; 17 (12) 2174-2187
    CrossrefPubMedGoogle Scholar
  • 45 Li Q, Laumonnier Y, Syrovets T, Simmet T. Plasmin triggers cytokine induction in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 2007; 27 (06) 1383-1389
    CrossrefPubMedGoogle Scholar
  • 46 Syrovets T, Lunov O, Simmet T. Plasmin as a proinflammatory cell activator. J Leukoc Biol 2012; 92 (03) 509-519
    CrossrefPubMedGoogle Scholar
  • 47 Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 2004; 61 (7-8): 873-885
    CrossrefPubMedGoogle Scholar
  • 48 Li X, Syrovets T, Genze F. , et al. Plasmin triggers chemotaxis of monocyte-derived dendritic cells through an Akt2-dependent pathway and promotes a T-helper type-1 response. Arterioscler Thromb Vasc Biol 2010; 30 (03) 582-590
    CrossrefPubMedGoogle Scholar
  • 49 Foley JH, Walton BL, Aleman MM. , et al. Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine 2016; 5: 175-182
    CrossrefPubMedGoogle Scholar
  • 50 Zhao XJ, Larkin TM, Lauver MA, Ahmad S, Ducruet AF. Tissue plasminogen activator mediates deleterious complement cascade activation in stroke. PLoS One 2017; 12 (07) e0180822
    CrossrefPubMedGoogle Scholar
  • 51 Foley JH. Plasmin(ogen) at the nexus of fibrinolysis, inflammation, and complement. Semin Thromb Hemost 2017; 43 (02) 135-142
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Das R, Ganapathy S, Settle M, Plow EF. Plasminogen promotes macrophage phagocytosis in mice. Blood 2014; 124 (05) 679-688
    PubMedGoogle Scholar
  • 53 Borg RJ, Samson AL, Au AE. , et al. Dendritic cell-mediated phagocytosis but not immune activation is enhanced by plasmin. PLoS One 2015; 10 (07) e0131216
    CrossrefPubMedGoogle Scholar
  • 54 Sato T, Sugioka K, Kodama-Takahashi A. , et al. Stimulation of phagocytic activity in cultured human corneal fibroblasts by plasminogen. Invest Ophthalmol Vis Sci 2019; 60 (13) 4205-4214
    CrossrefPubMedGoogle Scholar
  • 55 Draxler DF, Medcalf RL. The fibrinolytic system-more than fibrinolysis?. Transfus Med Rev 2015; 29 (02) 102-109
    CrossrefPubMedGoogle Scholar
  • 56 Draxler DF, Sashindranath M, Medcalf RL. Plasmin: a modulator of immune function. Semin Thromb Hemost 2017; 43 (02) 143-153
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Draxler DF, Yep K, Hanafi G. , et al. Tranexamic acid modulates the immune response and reduces postsurgical infection rates. Blood Adv 2019; 3 (10) 1598-1609
    CrossrefPubMedGoogle Scholar
  • 58 Ajjan RA, Gamlen T, Standeven KF. , et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood 2013; 122 (01) 134-142
    PubMedGoogle Scholar